Post-Exposure Prophylaxis After Fox Bite
For a previously unvaccinated person bitten by a fox, immediately initiate rabies post-exposure prophylaxis with thorough wound cleansing, rabies immune globulin (20 IU/kg infiltrated into/around wounds), and a 4-dose rabies vaccine series (days 0,3,7,14), plus ensure tetanus protection is current. 1
Immediate Wound Management
Begin with aggressive local wound care:
- Cleanse thoroughly with soap and water for 15 minutes 1
- Use a virucidal agent (povidone-iodine solution) if available 1
- Perform cautious debridement of devitalized tissue only—avoid enlarging the wound 2
- Do not suture the wound (infected wounds should remain open) 2
Rabies Risk Assessment
Foxes are high-risk rabies vectors and should be considered rabid unless proven otherwise. Wild carnivores like foxes warrant immediate rabies prophylaxis without waiting for animal testing results. The fox should be captured and tested if possible, but treatment should not be delayed.
Rabies Post-Exposure Prophylaxis Protocol
For Previously Unvaccinated Persons:
Human Rabies Immune Globulin (HRIG):
- Administer 20 IU/kg body weight on day 0 1
- Infiltrate the full dose into and around the wound(s) if anatomically feasible 1
- Inject any remaining volume intramuscularly at a site distant from vaccine administration 1
- Never administer HRIG in the same syringe or same anatomic site as the first vaccine dose 1
- If HRIG was not given on day 0, it can still be administered up to and including day 7 of the series 1, 3
- Do not exceed the recommended dose—excess HRIG can suppress active antibody production 1, 3
Rabies Vaccine:
- Use either HDCV (human diploid cell vaccine) or PCECV (purified chick embryo cell vaccine) 1
- Administer 4 doses of 1.0 mL intramuscularly on days 0,3,7, and 14 1
- Deltoid area for adults and older children; anterolateral thigh acceptable for young children 1
- Never use the gluteal area—results in diminished immune response 1
- Day 0 is the day the first dose is administered (start as soon as possible) 1
For Previously Vaccinated Persons:
If the patient has documented prior rabies vaccination:
Special Populations:
Immunocompromised patients require a 5-dose vaccine regimen (days 0,3,7,14, and 28) instead of the standard 4-dose series 1
Tetanus Protection
Verify tetanus immunization status immediately:
- If last tetanus toxoid was >5 years ago for contaminated wounds, or >10 years for clean wounds, administer 0.5 mL tetanus toxoid intramuscularly 2
- If tetanus status is unknown or incomplete primary series, give tetanus toxoid 2
- Administer at a different site than rabies vaccine
Critical Pitfalls to Avoid
- Never delay treatment waiting for animal testing—fox bites warrant immediate prophylaxis
- Do not skip HRIG in previously unvaccinated persons—it provides immediate passive immunity until active antibody production begins 1, 3
- Do not infiltrate HRIG and vaccine at the same site initially—can interfere with vaccine immunogenicity 1
- Do not use gluteal injection site—associated with vaccine failure 1
- Do not close/suture the wound—increases infection risk 2
Schedule Deviations
If doses are delayed by a few days, simply resume the schedule without restarting the series 3. For example, if the day 7 dose is given on day 10, continue with remaining doses maintaining the same intervals (days 17 and 31 in this example) 3.
Antibiotic Prophylaxis
Consider prophylactic antibiotics (amoxicillin-clavulanate preferred) for 3-5 days, particularly for:
- Hand wounds
- Deep puncture wounds
- Wounds near bones or joints
- Presentation >8 hours after injury 2
Follow-Up
- Reassess within 24 hours (phone or office visit) 2
- Monitor for signs of infection: increasing pain, erythema, purulent drainage, fever
- Watch for complications: cellulitis, abscess, osteomyelitis, septic arthritis 2
- If infection progresses despite treatment, hospitalize 2
The combination of proper wound care, HRIG, and the 4-dose vaccine series is highly effective—no treatment failures have been documented when this protocol is followed correctly in immunocompetent individuals. 1, 4